Hisun Pharmaceutical To Temporarily Produce Tamiflu Intermediates
This article was originally published in PharmAsia News
To guarantee drug supply for influenza prevention and control, China's National Development and Reform Commission has approved Hisun Pharmaceutical to temporarily produce Tamiflu intermediates. Prior to this, only Shanghai Pharmaceutical Group and HEC Group had obtained the local drug production authorization (PharmAsia News, May 11, 2009). Hisun will convert manufacturing facilities of its other drugs to produce Tamiflu intermediates, thus it cannot yet confirm output and cost of the product. The company ascribes the move to its growing R&D and production capacity, as well as the local government's preferential taxation policies for firms that adjust their drug production according to market demand. (Click here for more - Chinese Language)
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.